MUMBAI, India and LONDON and ROME and ZUG, Switzerland,

印度孟买、伦敦、罗马和瑞士楚格，

April 2, 2026

2026年4月2日

/PRNewswire/ -- Global pharma major Lupin Limited (Lupin)

/PRNewswire/ -- 全球制药巨头鲁宾有限公司 (Lupin)

(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN)

（BSE：500257）（NSE：LUPIN）（路透社：LUPIN.BO）（彭博：LPCIN）

announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe..

宣布已完成对VISUfarma B.V.（VISUfarma）的收购，这是一家专注于眼科的欧洲领先专业制药公司，由GHO Capital Partners LLP（GHO）出售。此次收购标志着Lupin在扩展其专科护理产品组合及加强在欧洲市场地位的战略中迈出了重要一步。

The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma's strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight..

VISUfarma的整合显著扩展了Lupin的眼科产品组合，现已涵盖超过60种品牌产品，覆盖干眼症、青光眼、眼睑卫生、睑缘炎、视网膜健康及特种营养品等领域。VISUfarma在意大利、英国、西班牙、德国和法国等欧洲关键市场拥有强大的商业影响力，其经验丰富的团队具备深厚的眼科专业知识、可信赖的关系网络以及对本地市场的深刻洞察，进一步巩固了这一地位。

VISUfarma enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

VISUfarma增强了Lupin应对全球对创新眼科护理解决方案不断增长的需求的能力，这一需求是由人口老龄化和糖尿病相关眼部并发症的负担日益加重所驱动的。

Vinita Gupta, CEO, Lupin

维尼塔·古普塔，鲁宾公司首席执行官

, said,

，说，

'

'

The VISUfarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build‑out of our specialty franchise.'.

VISUfarma的收购标志着Lupin一个非常令人兴奋的里程碑，增加了一个由超过60种创新眼健康产品组成的差异化产品组合，并得到了成熟的商业基础设施的支持。除了立即产生增值外，这项战略性收购还将扩大我们在欧洲的影响力，并加速我们专业特许经营业务的发展。

Paolo Cioccetti, CEO Italy, VISUfarma

保罗·乔切蒂，意大利首席执行官，VISUfarma

, added, 'We are thrilled to embark on this next chapter with Lupin. Their global expertise, vision, and commitment to ophthalmology make them the ideal partner to take VISUfarma to the next level. Together, we are confident that we can make a significant impact in advancing eye care across Europe and beyond.'.

，补充道：“我们非常高兴能与卢平开启这一新篇章。他们在全球的专业知识、愿景以及对眼科的承诺使他们成为将VISUfarma提升到新高度的理想合作伙伴。我们相信，共同努力下，我们可以在欧洲及更广泛地区推动眼科护理方面产生重大影响。”

About Lupin

关于Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S.

鲁宾有限公司是一家总部位于印度孟买的全球制药领导者，产品销往100多个市场。鲁宾专注于制药产品，包括品牌和通用制剂、复杂仿制药、生物技术产品以及活性药物成分。凭借全球医疗专业人士和消费者的信赖，该公司在印度和美国拥有强大的市场地位。

across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals.

横跨多个治疗领域，包括呼吸系统、心血管、抗糖尿病、抗感染、胃肠、中枢神经系统和妇女健康。Lupin在全球拥有15个最先进的制造基地和7个研究中心，以及超过24,000名专业人员的专职团队。

Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions..

通过其子公司——Lupin诊断、Lupin数字健康和Lupin制造解决方案，Lupin致力于改善患者的健康结果。

To know more, visit

欲了解更多信息，请访问

www.lupin.com

www.lupin.com

or follow us on LinkedIn

或在LinkedIn上关注我们

https://www.linkedin.com/company/lupin

https://www.linkedin.com/company/lupin

A

A

bout VISUfarma

关于VISUfarma

Founded in 2016 through the combination of the Italian company Visufarma SpA and the European commercial activities of the Nicox SA, VISUfarma is a specialty pharmaceutical company focused on ophthalmology. It generated €53m in revenue in 2025 across Italy, the UK, Spain, Germany, France and certain international markets.

VISUfarma 于2016年通过意大利公司 Visufarma SpA 与 Nicox SA 的欧洲商业活动合并而成，是一家专注于眼科的特色制药公司。2025年，该公司在意大利、英国、西班牙、德国、法国及某些国际市场实现了5300万欧元的收入。

VISUfarma was acquired by GHO Capital in 2016..

2016年，VISUfarma被GHO Capital收购。

Logo:

标志：

https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg

https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg

SOURCE Lupin Limited

来源：Lupin Limited

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示